Longitudinal evolution of ventricular function and cardiac magnetic resonance imaging tissue characteristics in tafamidis-treated transthyretin amyloid cardiomyopathy

Click to increase image sizeClick to decrease image size AcknowledgmentsWe thank Laura Morf, Lukas Lüthi and Sakthivel Subramaniam from the research study team for their excellent technical and administrative support.Disclosure statementThe authors declare no conflict of interest.Data availability statementThe data underlying this article will be shared on reasonable request to the corresponding author.Additional informationFundingDr. Dobner received a research grant for the Bern amyloidosis registry (B-CARE) (NCT04776824) on behalf of the institution (Inselspital Bern) from Pfizer. Dr. Bernhard reports a career development grant from the Swiss National Science Foundation. Y. Safarkhanlo received research funding from the Centre for Artificial Intelligence in Medicine Research Project Fund University Bern, outside of the submitted work. Dr. Gräni received research funding from the GAMBIT foundation for the current study. Further Dr. Gräni received funding from the Swiss National Science Foundation, Innosuisse and from the Centre for Artificial Intelligence in Medicine Research Project Fund University Bern, outside of the submitted work. All other authors report no conflicts.